David Groth
Non-Executive Chairman
Co-founder of Integra Advisory; 20+ years advising on IPOs, raisings and M&A, including 18 years at Wilson HTM as CEO.
New treatments for neurodegenerative disease
Alsonex develops first-in-class therapies for the diseases medicine has struggled hardest to treat — advancing its lead compound, ALS-205, toward a new option for people living with Motor Neuron Disease.
Our principal commercial objective
A focused path from the laboratory to the patient.
The objective is to develop a new treatment option for people with neurodegenerative disease — and to enhance shareholder value through the clinical development of ALS-205.
- The lead compound has completed Phase I (Single & Multiple Ascending Dose) in healthy volunteers, establishing a suitable dose.
- A Phase Ib trial in subjects with MND demonstrated safe target engagement in the intended population.
- Additional indications include Alzheimer's and Huntington's disease.
Development pipeline
One molecule, a widening clinical frontier
ALS-205
Motor Neuron Disease (MND / ALS)
Discovery
Preclinical
Phase I
Phase Ib
Phase II
ALS-205
Alzheimer's Disease
Discovery
Preclinical
Phase I
Phase Ib
Phase II
ALS-205
Huntington's Disease
Discovery
Preclinical
Phase I
Phase Ib
Phase II
Our leadership team
Experienced drug developers and proven operators
Alan Robertson
CEO & Managing Director
CEO of Pharmaxis for 14 years, raising $350M+; created PXS4728 (Boehringer Ingelheim) and invented Zomig at Wellcome.
Trent Woodruff
Scientific Advisor
ARC Future Fellow at UQ researching the complement system across ALS, Huntington's and Parkinson's disease.
For investors & partners
Partner with us to bring ALS-205 to patients.
We advance our programmes to proof-of-concept, then share later-stage development with the right pharmaceutical partner. Let's talk.
Contact the team